KDT-3594 ( DrugBank: KDT-3594 )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	4

6. パーキンソン病

---

臨床試験数 : 2,307 /  薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2031210089	15/05/2021	13/05/2021	A clinical study of KDT-3594 in Japanese patients with early Parkinson's disease.	A phase II clinical study of KDT-3594 in Japanese patients with early Parkinson's disease.	Parkinson's disease	Oral and titrated doses of KDT-3594	Shimizu Yoshitaka	NULL	Complete	>= 20age old	< 80age old	Both	6	Phase 2	Japan
2	NCT04867551 (ClinicalTrials.gov)	May 15, 2021	27/4/2021	A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease	A Phase II Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease	Parkinson Disease	Drug: KDT-3594	Kissei Pharmaceutical Co., Ltd.	NULL	Completed	20 Years	79 Years	All	7	Phase 2	Japan
3	NCT03845387 (ClinicalTrials.gov)	February 26, 2019	15/2/2019	A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.	A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.	Parkinson Disease	Drug: KDT-3594;Drug: Pramipexole	Kissei Pharmaceutical Co., Ltd.	NULL	Completed	20 Years	79 Years	All	74	Phase 2	Japan
4	NCT03068481 (ClinicalTrials.gov)	February 20, 2017	26/2/2017	Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease	A Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease	Parkinson Disease	Drug: KDT-3594;Drug: Placebo	Kissei Pharmaceutical Co., Ltd.	NULL	Completed	20 Years	74 Years	All	36	Phase 1	Japan